A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study

Abstract

Georges Juvelekian,1 Waleed El-Sorougi,2 Chaicharn Pothirat,3 Faisal Yunus,4 Teresita De Guia,5 Han-Pin Kuo,6 Shalma Basu Patnaik,7 Virginia Pilipovic8 1St Georges Hospital University Medical Center, Ashrafieh, Beirut, Lebanon; 2Chest Department, Faculty of Medicine, Helwan University, Cairo, Egypt; 3Division of Pulmonary and Critical Care, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 4Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of Indonesia, Persahabatan Hospital, Jakarta Timur, Indonesia; 5Department of Pulmonary Medicine, Philippine Heart Center, Quezon City, Philippines; 6Linkou Chang Gung Memorial Hospital, Taoyuan Hsien, Taiwan, ROC; 7Novartis Healthcare Pvt Ltd, Rangareddy, Telangana, India; 8Novartis Pharma AG, Basel, Switzerland Aim: INFLOW (INdacaterol eFfectiveness and utiLizatiOn in COPD: real World evaluation) was a prospective, noninterventional study assessing the effectiveness and safety of long-acting bronchodilators in patients with chronic obstructive pulmonary disease (COPD) from the Middle East, Asia, and South Africa.Methods: Patients newly prescribed or switched to indacaterol or other long-acting β2-agonist (LABA), or tiotropium (monotherapy or in combination) were evaluated over 6 months. The primary endpoint was the clinical COPD questionnaire overall score at the end of the study.Results: Data were analyzed from 1,710 patients (mean postbronchodilator forced expiratory volume in 1 second, 59% predicted) who received indacaterol (n=1,179), other LABA (n=68), tiotropium (n=271), indacaterol plus tiotropium (n=167), or other LABA plus tiotropium (n=25). Across treatments, clinical COPD questionnaire overall score improved from baseline by 0.81–1.26 points (all P<0.0001), 63%–84% of patients were satisfied/very satisfied, and physicians rated effectiveness as good/very good in 63%–80% of cases. The indacaterol inhaler was rated easy/very easy to use by the majority of patients, and physicians considered its use clearly understood by most patients. All treatments had acceptable tolerability.Conclusion: In real life clinical practice across a diverse region, indacaterol and other long-acting bronchodilators improved health status and were well regarded by patients and physicians. Keywords: long-acting bronchodilator, indacaterol, chronic obstructive pulmonary disease, noninterventional study, Middle East, Asia